Live attenuated tetravalent dengue virus host range vaccine is immunogenic in African green monkeys following a single vaccination

Journal of Virology

Volumn 88, Issue 12, 2014, Pages 6729-6742

  Briggs, Caitlin M ^a   Smith, Katherine M ^a   Piper, Amanda ^b   Huitt, Emerson ^a   Spears, Carla J ^a   Quiles, Michelle ^a   Ribeiro, Mariana ^b   Thomas, Malcolm E ^a   Brown, Dennis T ^b   Hernandez, Raquel ^b  

^a Arbovax Inc   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE; E PROTEIN; LIVE VACCINE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CHLOROCEBUS AETHIOPS; CONTROLLED STUDY; DENGUE; DENGUE VIRUS; DRUG EFFICACY; DRUG SAFETY; HOST RANGE; IMMUNE RESPONSE; IMMUNOGENICITY; IN VIVO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; SEROCONVERSION; SINGLE DRUG DOSE; VACCINATION; VIREMIA; VIRUS CELL INTERACTION; VIRUS LOAD; VIRUS NEUTRALIZATION; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; ANTIBODIES, VIRAL; CERCOPITHECUS AETHIOPS; DENGUE; DENGUE VACCINES; DENGUE VIRUS; HOST SPECIFICITY; HUMANS; SPECIES SPECIFICITY; VACCINATION; VACCINES, ATTENUATED; VIRAL ENVELOPE PROTEINS;

EID: 84901342788     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00541-14     Document Type: Article

References (63)

1. WHO.2014. Dengue and severe dengue. Fact sheet no. 17.WHO, Geneva, Switzerland. http://www.who.int/mediacentre/factsheets/fs117/en/.
2. Halstead SB. 1980. Immunological parameters of Togavirus disease syndromes, p 107-168. In Schlesinger RW (ed), The togaviruses: biology, structure, replication. Academic Press, New York, NY.
3. Henchal EA, Putnak JR. 1990. The dengue viruses. Clin. Microbiol. Rev. 3:376-396.
4. Gubler DJ. 2006. Dengue/dengue haemorrhagic fever: history and current status. Novartis Found. Symp. 277:3-16, 16-22. http://dx.doi.org/10.1002/0470058005.ch2.
5. WHO. 2012. Dengue/dengue haemorrhagic fever. WHO, Geneva, Switzerland. http://www.who.int/csr/disease/dengue/en/.
6. Durbin AP, Kirkpatrick BD, Pierce KK, Elwood D, Larsson CJ, Lindow JC, Tibery C, Sabundayo BP, Shaffer D, Talaat KR, Hynes NA, Wanionek K, Carmolli MP, Luke CJ, Murphy BR, Subbarao K, Whitehead SS. 2013. A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial. J. Infect. Dis. 207:957-965. http://dx.doi.org/10.1093/infdis/jis936.
7. Morens DM, Fauci AS. 2008. Dengue and hemorrhagic fever:a potential threat to public health in the United States. JAMA 299:214-216. http://dx.doi.org/10.1001/jama.2007.31-a.
8. Adalja AA, Sell TK, Bouri N, Franco C. 2012. Lessons learned during dengue outbreaks in the United States, 2001-2011. Emerg. Infect. Dis. 18:608-614. http://dx.doi.org/10.3201/eid1804.110968.
9. Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, Jiwariyavej V, Dulyachai W, Pengsaa K, Wartel TA, Moureau A, Saville M, Bouckenooghe A, Viviani S, Tornieporth NG, Lang J. 2012. Protective efficacy of the recombinant, liveattenuated, CYDtetravalent dengue vaccine in Thai schoolchildren:a randomised, controlled phase 2b trial. Lancet 380:1559-1567. http://dx.doi.org/10.1016/S0140-6736(12)61428-7.
10. Huang CY, Kinney RM, Livengood JA, Bolling B, Arguello JJ, Luy BE, Silengo SJ, Boroughs KL, Stovall JL, Kalanidhi AP, Brault AC, Osorio JE, Stinchcomb DT. 2013. Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax). PLoS Negl. Trop. Dis. 7(5):e2243. http://dx.doi.org/10.1371/journal.pntd.0002243.
11. Thomas SJ, Eckels KH, Carletti I, De La Barrera R, Dessy F, Fernandez S, Putnak R, Toussaint JF, Sun W, Bauer K, Gibbons RV, Innis BL. 2013. A phase II, randomized, safety and immunogenicity study of a rederived, live-attenuated dengue virus vaccine in healthy adults. Am. J. Trop. Med. Hyg. 88:73-88. http://dx.doi.org/10.4269/ajtmh.2012.12-0361.
12. Durbin AP, Whitehead SS. 2013. The dengue human challenge model:has the time come to accept this challenge? J. Infect. Dis. 207:697-699. http://dx.doi.org/10.1093/infdis/jis749.
13. Lauring AS, Jones JO, Andino R. 2010. Rationalizing the development of live attenuated virus vaccines. Nat. Biotechnol. 28:573-579. http://dx.doi.org/10.1038/nbt.1635.
14. de Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP, Wahala WM, White LJ, Diamond MS, Baric RS, Crowe JE, Jr, de Silva AM. 2012. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc. Natl. Acad. Sci. U. S. A. 109:7439-7444. http://dx.doi.org/10.1073/pnas.1200566109.
15. Stephens HA, Klaythong R, Sirikong M, Vaughn DW, Green S, Kalayanarooj S, Endy TP, Libraty DH, Nisalak A, Innis BL, Rothman AL, Ennis FA, Chandanayingyong D. 2002. HLA-A and-B allele associations with secondary dengue virus infections correlate with disease severity andthe infecting viral serotype in ethnic Thais. Tissue Antigens 60:309-318. http://dx.doi.org/10.1034/j.1399-0039.2002.600405.x.
16. Weiskopf D, Angelo MA, de Azeredo EL, Sidney J, Greenbaum JA, Fernando AN, Broadwater A, Kolla RV, De Silva AD, de Silva AM, Mattia KA, Doranz BJ, Grey HM, Shresta S, Peters B, Sette A. 2013. Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proc. Natl. Acad. Sci. U. S. A. 110:E2046-E2053. http://dx.doi.org/10.1073/pnas.1305227110.
17. Smith KM, Nanda K, Spears CJ, Piper A, Ribeiro M, Quiles M, Briggs CM, Thomas GS, Thomas ME, Brown DT, Hernandez R, McCarl V. 2012. Testing of novel dengue virus 2 vaccines in African green monkeys:safety, immunogenicity, and efficacy. Am. J. Trop. Med. Hyg. 87:743-753. http://dx.doi.org/10.4269/ajtmh.2012.12-0004.
18. Hernandez R, Lee H, Nelson C, Brown DT. 2000. A single deletion in the membrane-proximal region of the Sindbis virus glycoprotein E2 endodomain blocks virus assembly. J. Virol. 74:4220-4228. http://dx.doi.org/10.1128/JVI.74.9.4220-4228.2000.
19. Hernandez R, Sinodis C, Horton M, Ferreira D, Yang C, Brown DT. 2003. Deletions in the transmembrane domain of a Sindbis virus glycoprotein alter virus infectivity, stability, and host range. J. Virol. 77:12710-12719. http://dx.doi.org/10.1128/JVI.77.23.12710-12719.2003.
20. Nguyen NM, Thi Hue Kien D, Tuan TV, Quyen NT, Tran CN, Vo Thi L, Thi DL, Nguyen HL, Farrar JJ, Holmes EC, Rabaa MA, Bryant JE, Nguyen TT, Nguyen HT, Nguyen LT, Pham MP, Luong TT, Wills B, Nguyen CV, Wolbers M, Simmons CP. 2013. Host and viral features of human dengue cases shape the population of infected and infectious Aedes aegypti mosquitoes. Proc. Natl. Acad. Sci. U. S. A. 110:9072-9077. http://dx.doi.org/10.1073/pnas.1303395110.
21. Bomers MK, Lettinga KD, van Gorp EC, Martina BE, Peerbooms PG, Veenstra J. 2009. Dengue infection with fatal ending. Ned. Tijdschr. Geneeskd. 153:A725. (In Dutch.)
22. Martin J, Hermida L, Castro J, Romero Y, Cardosa J, Guillen G. 2009. Viremia and the magnitude of the immune response upon infection of green monkeys with dengue virus type 2 are strain-dependent. Curr. Microbiol. 59:579-583. http://dx.doi.org/10.1007/s00284-009-9488-6.
23. Kinney RM, Butrapet S, Chang GJ, Tsuchiya KR, Roehrig JT, Bhamarapravati N, Gubler DJ. 1997. Construction of infectious cDNA clones for dengue 2 virus:strain 16681 and its attenuated vaccine derivative, strain PDK-53. Virology 230:300-308. http://dx.doi.org/10.1006/viro.1997.8500.
24. Puri B, Nelson W, Porter KR, Henchal EA, Hayes CG. 1998. Complete nucleotide sequence analysis of a Western Pacific dengue-1 virus strain. Virus Genes 17:85-88. http://dx.doi.org/10.1023/A:1008009202695.
25. Puri B, Polo S, Hayes CG, Falgout B. 2000. Construction of a full length infectious clone for dengue-1 virus Western Pacific,74 strain. Virus Genes 20:57-63. http://dx.doi.org/10.1023/A:1008160123754.
26. Kelly EP, Puri B, Sun W, Falgout B. 2010. Identification of mutations in a candidate dengue 4 vaccine strain 341750 PDK20 and construction of a full-length cDNA clone of the PDK20 vaccine candidate. Vaccine 28:3030-3037.
27. Puri B, Nelson WM, Henchal EA, Hoke CH, Eckels KH, Dubois DR, Porter KR, Hayes CG. 1997. Molecular analysis of dengue virus attenuation after serial passage in primary dog kidney cells. J. Gen. Virol. 78(Part 9):2287-2291.
28. Kelly EP, Polo S, Sun W, Falgout B. 2011. Evolution of attenuating mutations in dengue-2 strain S16803 PDK50 vaccine and comparison of growth kinetics with parent virus. Virus Genes 43:18-26. http://dx.doi.org/10.1007/s11262-011-0602-z.
29. Smith KM, Nanda K, Spears CJ, Ribeiro M, Vancini R, Piper A, Thomas GS, Thomas ME, Brown DT, Hernandez R. 2011. Structural mutants of dengue virus 2 transmembrane domains exhibit host-range phenotype. Virol. J. 8:289. http://dx.doi.org/10.1186/1743-422X-8-289.
30. Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, Jiwariyavej V, Dulyachai W, Pengsaa K, Wartel TA, Moureau A, Saville M, Bouckenooghe A, Viviani S, Tornieporth NG, Lang J. 2012. Protective efficacy of the recombinant, liveattenuated, CYD tetravalent dengue vaccine in Thai schoolchildren:a randomised, controlled phase 2b trial. Lancet 380:1559-1567. http://dx.doi.org/10.1016/S0140-6736(12)61428-7.
31. Halstead SB. 2012. Dengue vaccine development:a 75% solution? Lancet 380:1535-1536. http://dx.doi.org/10.1016/S0140-6736(12)61510-4.
32. Halstead S. 2013. Identifying protective dengue vaccines:Guide to mastering an empirical process. Vaccine 31:4501-4507. http://dx.doi.org/10.1016/j.vaccine.2013.06.079.
33. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn S, Endy TP, Raengsakulrach B, Rothman AL, Ennis FA, Nisalak A. 2000. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J. Infect. Dis. 181:2-9. http://dx.doi.org/10.1086/315215.
34. Sangkawibha N, Rojanasuphot S, Ahandrik S, Viriyapongse S, Jatanasen S, Salitul V, Phanthumachinda B, Halstead SB. 1984. Risk factors in dengue shock syndrome:a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak. Am. J. Epidemiol. 120:653-669.
35. Mahalingam S, Herring BL, Halstead SB. 2013. Call to action for dengue vaccine failure. Emerg. Infect. Dis. 19:1335-1337. http://dx.doi.org/10.3201/eid1908.121864.
36. van Panhuis WG, Gibbons RV, Endy TP, Rothman AL, Srikiatkhachorn A, Nisalak A, Burke DS, Cummings DAT. 2010. Inferring the serotype associated with dengue virus infections on the basis of pre-and postinfection neutralizing antibody titers. J. Infect. Dis. 202:1002-1010. http://dx.doi.org/10.1086/656141.
37. Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L, Quyen NT, Sukupolvi-Petty S, Navarro-Sanchez E, Young PR, de Silva AM, Rey FA, Varani L, Whitehead SS, Diamond MS, Harris E, Lanzavecchia A, Sallusto F. 2010. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 8:271-283. http://dx.doi.org/10.1016/j.chom.2010.08.007.
38. Zhang X, Sheng J, Plevka P, Kuhn RJ, Diamond MS, Rossmann MG. 2013. Dengue structure differs at the temperatures of its human and mosquito hosts. Proc. Natl. Acad. Sci. U. S. A. 110:6795-6799. http://dx.doi.org/10.1073/pnas.1304300110.
39. Fibriansah G, Ng TS, Kostyuchenko VA, Lee J, Lee S, Wang J, Lok SM. 2013. Structural changes in dengue virus when exposed to a temperature of 37 degrees C. J. Virol. 87:7585-7592. http://dx.doi.org/10.1128/JVI.00757-13.
40. He L, Piper A, Meilleur F, Myles DA, Hernandez R, Brown DT, Heller WT. 2010. The structure of Sindbis virus produced from vertebrate and invertebrate hosts as determined by small-angle neutron scattering. J. Virol. 84:5270-5276. http://dx.doi.org/10.1128/JVI.00044-10.
41. Kostyuchenko VA, Chew PL, Ng TS, Lok SM. 2014. Near-atomic resolution cryo-electron microscopic structure of dengue serotype 4 virus. J. Virol. 88:477-482. http://dx.doi.org/10.1128/JVI.02641-13.
42. Sabchareon A, Lang J, Chanthavanich P, Yoksan S, Forrat R, Attanath P, Sirivichayakul C, Pengsaa K, Pojjaroen-Anant C, Chokejindachai W, Jagsudee A, Saluzzo JF, Bhamarapravati N. 2002. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers:role of serotype concentration, ratio, and multiple doses. Am. J. Trop. Med. Hyg. 66:264-272.
43. Kitchener S, Nissen M, Nasveld P, Forrat R, Yoksan S, Lang J, Saluzzo JF. 2006. Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults. Vaccine 24:1238-1241. http://dx.doi.org/10.1016/j.vaccine.2005.09.029.
44. Morrison D, Legg TJ, Billings CW, Forrat R, Yoksan S, Lang J. 2010. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J. Infect. Dis. 201:370-377. http://dx.doi.org/10.1086/649916.
45. Sun W, Cunningham D, Wasserman SS, Perry J, Putnak JR, Eckels KH, Vaughn DW, Thomas SJ, Kanesa-Thasan N, Innis BL, Edelman R. 2009. Phase 2 clinical trial of three formulations of tetravalent liveattenuated dengue vaccine in flavivirus-naive adults. Hum. Vaccin. 5:33-40. http://dx.doi.org/10.4161/hv.5.1.6348.
46. Pandrea I, Apetrei C, Dufour J, Dillon N, Barbercheck J, Metzger M, Jacquelin B, Bohm R, Marx PA, Barre-Sinoussi F, Hirsch VM, Muller-Trutwin MC, Lackner AA, Veazey RS. 2006. Simian immunodeficiency virus SIVagm. sab infection of Caribbean African green monkeys:a new model for the study of SIV pathogenesis in natural hosts. J. Virol. 80:4858-4867. http://dx.doi.org/10.1128/JVI.80.10.4858-4867.2006.
47. Durbin AP, Schmidt A, Elwood D, Wanionek KA, Lovchik J, Thumar B, Murphy BR, Whitehead SS. 2011. Heterotypic dengue infection with live attenuated monotypic dengue virus vaccines:implications for vaccination of populations in areas where dengue is endemic. J. Infect. Dis. 203:327-334. http://dx.doi.org/10.1093/infdis/jiq059.
48. Durbin AP, Whitehead SS. 2011. Next-generation dengue vaccines:novelstrategies currently under development. Viruses 3:1800-1814. http://dx.doi.org/10.3390/v3101800.
49. Barban V, Munoz-Jordan JL, Santiago GA, Mantel N, Girerd Y, Gulia S, Claude JB, Lang J. 2012. Broad neutralization of wild-type dengue virus isolates following immunization in monkeys with a tetravalent dengue vaccine based on chimeric yellow fever 17D/dengue viruses. Virology 429:91-98. http://dx.doi.org/10.1016/j.virol.2012.03.007.
50. Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, Jiwariyavej V, Dulyachai W, Pengsaa K, Wartel TA, Moureau A, Saville M, Bouckenooghe A, Viviani S, Tornieporth NG, Lang J. 2012. Protective efficacy of the recombinant, liveattenuated, CYD tetravalent dengue vaccine in Thai schoolchildren:a randomised, controlled phase 2b trial. Lancet 380:1559-1567. http://dx.doi.org/10.1016/S0140-6736(12)61428-7.
51. Sun W, Eckels KH, Putnak JR, Lyons AG, Thomas SJ, Vaughn DW, Gibbons RV, Fernandez S, Gunther VJ, Mammen MP, Jr, Statler JD, Innis BL. 2013. Experimental dengue virus challenge of human subjects previously vaccinated with live attenuated tetravalent dengue vaccines. J. Infect. Dis. 207:700-708.
52. Sun W, Edelman R, Kanesa-Thasan N, Eckels KH, Putnak JR, King AD, Houng HS, Tang D, Scherer JM, Hoke CH, Jr, Innis BL. 2003. Vaccination of human volunteers with monovalent and tetravalent liveattenuated dengue vaccine candidates. Am. J. Trop. Med. Hyg. 69(6 Suppl):24-31.
53. Sun W, Nisalak A, Gettayacamin M, Eckels KH, Putnak JR, Vaughn DW, Innis BL, Thomas SJ, Endy TP. 2006. Protection of Rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination. J. Infect. Dis. 193:1658-1665. http://dx.doi.org/10.1086/503372.
54. Redmond DE, Jr, Bjugstad KB, Teng YD, Ourednik V, Ourednik J, Wakeman DR, Parsons XH, Gonzalez R, Blanchard BC, Kim SU, Gu Z, Lipton SA, Markakis EA, Roth RH, Elsworth JD, Sladek JR, Jr, Sidman RL, Snyder EY. 2007. Behavioral improvement in a primate Parkinson's model is associated with multiple homeostatic effects of human neural stem cells. Proc. Natl. Acad. Sci. U. S. A. 104:12175-12180. http://dx.doi.org/10.1073/pnas.0704091104.
55. Lemere CA, Beierschmitt A, Iglesias M, Spooner ET, Bloom JK, Leverone JF, Zheng JB, Seabrook TJ, Louard D, Li D, Selkoe DJ, Palmour RM, Ervin FR. 2004. Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet. Am. J. Pathol. 165:283-297. http://dx.doi.org/10.1016/S0002-9440(10)63296-8.
56. Goldstein S, Brown CR, Ourmanov I, Pandrea I, Buckler-White A, Erb C, Nandi JS, Foster GJ, Autissier P, Schmitz JE, Hirsch VM. 2006. Comparison of simian immunodeficiency virus SIVagmVer replication and CD4+T-cell dynamics in vervet and sabaeus African green monkeys. J. Virol. 80:4868-4877. http://dx.doi.org/10.1128/JVI.80.10.4868-4877.2006.
57. Simmons JS, St John JH, Reynolds FHK. 1931. Experimental studies of dengue. Philippine J. Sci. 44:1-247.
58. Martin J, Hermida L, Castro J, Lazo L, Martinez R, Gil L, Romero Y, Puente P, Zaragoza S, Cosme K, Guzman MG, Cardosa J, Guillen G. 2009. Viremia and antibody response in green monkeys (Chlorocebus aethiops sabaeus) infected with dengue virus type 2:a potential model for vaccine testing. Microbiol. Immunol. 53:216-223. http://dx.doi.org/10.1111/j.1348-0421.2009.00112.x.
59. Ammerman NC, Beier-Sexton M, Azad AF. 2008. Growth and maintenance of Vero cell lines. Curr. Protoc. Microbiol. Appendix:Appendix-4E. http://dx.doi.org/10.1002/9780471729259.mca04es11.
60. Treanor JJ, El Sahly H, King J, Graham I, Izikson R, Kohberger R, Patriarca P, Cox M. 2011. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok(R)) against influenza in healthy adults:a randomized, placebo-controlled trial. Vaccine 29:7733-7739. http://dx.doi.org/10.1016/j.vaccine.2011.07.128.
61. Cox MM, Hollister JR. 2009. FluBlok, a next generation influenza vaccine manufactured in insect cells. Biologicals 37:182-189. http://dx.doi.org/10.1016/j.biologicals.2009.02.014.
62. Baxter R, Patriarca PA, Ensor K, Izikson R, Goldenthal KL, Cox MM. 2011. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok(R) trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age. Vaccine 29:2272-2278. http://dx.doi.org/10.1016/j.vaccine.2011.01.039.
63. National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC.